AIM-HIGH misses its mark, but hits Abbott and the "HDL hypothesis"
This article was originally published in Scrip
Executive Summary
Hopes of taking cardiovascular adverse event prevention to the next level by raising levels of the "good" HDL-cholesterol have been dealt another blow with the failure of the AIM-HIGH study of Abbott's extended-release niacin product Niaspan.